Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell?

Key Points

• Genmab A/S's stock price has recently surpassed its 50-day moving average of $214.82, trading at $222.50 with a high of $223.00 during the day.
• The company achieved a quarterly EPS of $3.05, exceeding expectations by $1.17, alongside a revenue of $765.14 million.
• Genmab A/S specializes in antibody therapeutics for cancer treatment and markets several products, including DARZALEX and teprotumumab.

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $214.82 and traded as high as $223.00. Genmab A/S shares last traded at $222.50, with a volume of 10 shares.

Genmab A/S Stock Performance

The business's 50 day moving average is $215.25 and its 200 day moving average is $206.75. The stock has a market capitalization of $14.29 billion, a PE ratio of 10.86 and a beta of 0.93.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.23%. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.